Incidence and prevalence of systemic sclerosis in Thailand in year 2017-2020: a database from the Ministry of Public Health.
Asia-Pacific
Epidemiology
Incidence
Prevalence
Systemic sclerosis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
22
12
2022
accepted:
14
02
2023
revised:
11
02
2023
medline:
16
6
2023
pubmed:
10
3
2023
entrez:
9
3
2023
Statut:
ppublish
Résumé
A better understanding of the epidemiological profile of systemic sclerosis (SSc) in Thais could improve care, human resource deployment, and public health budgeting. We aimed to determine the incidence and prevalence of SSc in Thailand between 2017 and 2020. A descriptive epidemiological study was performed using the Information and Communication Technology Center, Ministry of Public Health database, comprising all types of healthcare providers during the study period. Demographic data of patients having a primary diagnosis of M34 systemic sclerosis and over 18 years of age between 2017 and 2020 were reviewed. The incidence and prevalence of SSc were calculated as well as their respective 95% confidence intervals (CIs). The number of SSc cases in 2017 was 15,920 from a total Thai population of 65,204,797. The prevalence of SSc in 2017 was 24.4 per 100,000 populations (95% CI 24.0-24.8). The prevalence of SSc among women was 2 times greater than among men (32.7 vs. 15.8 per 100,000). The incidence of SSc was stable from 2018 to 2019 but dropped slightly in 2020 (7.2, 7.6, and 6.8 per 100,000 person-years, respectively). Most SSc cases were in northeastern Thailand (11.6, 12.1, and 11.1 per 100,000 person-years from 2018 to 2020, respectively) and the peak was between 60 and 69 years of age (24.6, 23.8, and 20.9 per 100,000 person-years from 2018 to 2020, respectively). SSc is a rare disease among Thais. The disease was commonly revealed in late middle-aged women with a peak at age 60-69 years, mainly from the northeast regions. The incidence remained stable during the study period, albeit during the emergence of the coronavirus pandemic a slight decline was recorded. Key Points • The incidence and prevalence of systemic sclerosis (SSc) vary across ethnic populations. • There is a lack of epidemiology research of SSc since the 2013 ACR/EULAR Classification Criteria for Scleroderma was adopted among Thais included Asia-Pacific population as the population has some different clinical features than those reported among Caucasians. • SSc is a rare connective disease among Thais and commonly presents in late middle-aged group of both genders, mainly in Thailand's northern and northeastern regions. • When compare to the epidemiology of SSc in Asia-Pacific, the prevalence of SSc in Thais was higher than among East Asians and the Indian population and the incidence of SSc among Thais was greater than the other Asia-Pacific population including Australian.
Sections du résumé
BACKGROUND
BACKGROUND
A better understanding of the epidemiological profile of systemic sclerosis (SSc) in Thais could improve care, human resource deployment, and public health budgeting.
OBJECTIVES
OBJECTIVE
We aimed to determine the incidence and prevalence of SSc in Thailand between 2017 and 2020.
METHODS
METHODS
A descriptive epidemiological study was performed using the Information and Communication Technology Center, Ministry of Public Health database, comprising all types of healthcare providers during the study period. Demographic data of patients having a primary diagnosis of M34 systemic sclerosis and over 18 years of age between 2017 and 2020 were reviewed. The incidence and prevalence of SSc were calculated as well as their respective 95% confidence intervals (CIs).
RESULTS
RESULTS
The number of SSc cases in 2017 was 15,920 from a total Thai population of 65,204,797. The prevalence of SSc in 2017 was 24.4 per 100,000 populations (95% CI 24.0-24.8). The prevalence of SSc among women was 2 times greater than among men (32.7 vs. 15.8 per 100,000). The incidence of SSc was stable from 2018 to 2019 but dropped slightly in 2020 (7.2, 7.6, and 6.8 per 100,000 person-years, respectively). Most SSc cases were in northeastern Thailand (11.6, 12.1, and 11.1 per 100,000 person-years from 2018 to 2020, respectively) and the peak was between 60 and 69 years of age (24.6, 23.8, and 20.9 per 100,000 person-years from 2018 to 2020, respectively).
CONCLUSION
CONCLUSIONS
SSc is a rare disease among Thais. The disease was commonly revealed in late middle-aged women with a peak at age 60-69 years, mainly from the northeast regions. The incidence remained stable during the study period, albeit during the emergence of the coronavirus pandemic a slight decline was recorded. Key Points • The incidence and prevalence of systemic sclerosis (SSc) vary across ethnic populations. • There is a lack of epidemiology research of SSc since the 2013 ACR/EULAR Classification Criteria for Scleroderma was adopted among Thais included Asia-Pacific population as the population has some different clinical features than those reported among Caucasians. • SSc is a rare connective disease among Thais and commonly presents in late middle-aged group of both genders, mainly in Thailand's northern and northeastern regions. • When compare to the epidemiology of SSc in Asia-Pacific, the prevalence of SSc in Thais was higher than among East Asians and the Indian population and the incidence of SSc among Thais was greater than the other Asia-Pacific population including Australian.
Identifiants
pubmed: 36894730
doi: 10.1007/s10067-023-06550-7
pii: 10.1007/s10067-023-06550-7
pmc: PMC9998257
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1767-1774Informations de copyright
© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
Ann Rheum Dis. 2011 Mar;70(3):476-81
pubmed: 21081523
Rheumatol Int. 2012 Sep;32(9):2883-8
pubmed: 21898056
Intern Med J. 2001 May-Jun;31(4):220-9
pubmed: 11456035
Ann Rheum Dis. 1994 Aug;53(8):502-5
pubmed: 7944633
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
J Med Assoc Thai. 2014 Jan;97(1):28-35
pubmed: 24701726
Open Rheumatol J. 2011;5:59-63
pubmed: 22046208
Scand J Rheumatol. 2011;40(5):373-8
pubmed: 21388247
Rheumatol Int. 2013 Aug;33(8):2069-77
pubmed: 23404077
Rheumatology (Oxford). 2012 Apr;51(4):721-9
pubmed: 22179737
Semin Arthritis Rheum. 2014 Oct;44(2):208-19
pubmed: 24931517
Rheumatology (Oxford). 2021 Jul 1;60(7):3121-3133
pubmed: 33630060
Rheumatol Int. 2013 Aug;33(8):1943-50
pubmed: 23344826
Sci Rep. 2020 Jun 30;10(1):10627
pubmed: 32606345
Semin Arthritis Rheum. 2020 Jun;50(3):526-533
pubmed: 31852583
Medicine (Baltimore). 2002 Mar;81(2):139-53
pubmed: 11889413
J Rheumatol. 2001 Jul;28(7):1573-6
pubmed: 11469464
Adv Ther. 2022 May;39(5):2222-2235
pubmed: 35316503
Aust N Z J Med. 1999 Feb;29(1):42-50
pubmed: 10200812
Intern Med J. 2006 Aug;36(8):489-97
pubmed: 16866652
Ann Rheum Dis. 2015 Nov;74(11):1983-9
pubmed: 24938285
Mod Rheumatol. 2012 Apr;22(2):272-9
pubmed: 21874591
Arthritis Care Res (Hoboken). 2013 Feb;65(2):244-50
pubmed: 22899470
Aust N Z J Med. 1995 Dec;25(6):688-94
pubmed: 8770332
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):76-81
pubmed: 29998834
Ann Rheum Dis. 2005 Jul;64(7):1107
pubmed: 15958775
Rheumatol Int. 2017 Nov;37(11):1825-1833
pubmed: 28819792
Lupus. 2019 Jan;28(1):3-10
pubmed: 30501463
Arch Dermatol Res. 1991;283(6):366-71
pubmed: 1796818
Sci Rep. 2021 Apr 12;11(1):7983
pubmed: 33846466
Arthritis Rheum. 1980 May;23(5):581-90
pubmed: 7378088
Arthritis Care Res (Hoboken). 2016 Dec;68(12):1843-1848
pubmed: 26946215
Int J Rheum Dis. 2020 Jul;23(7):945-957
pubmed: 32420701
Br J Dermatol. 2018 Jan;178(1):e37-e39
pubmed: 28734000
Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-10-4
pubmed: 24144459
Semin Arthritis Rheum. 2001 Apr;30(5):332-46
pubmed: 11303306